Become a member to receive our newsletter and get unrestricted access to downloadable slidekits...
A confirmation email has been sent to
Please click on the Activation Link to activate your account.
If you don't receive our email, please check your spam folder.
Already registered?
Neved registered?
Forgot your codes?
EURIKA (European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice) is a cross-sectional observational study of primary and secondary prevention care across Europe. Given that atherogenic dyslipidaemia is an important contributor to lipid-related residual cardiovascular risk, especially in patients with insulin resistant conditions, the current report investigated the prevalence of this dyslipidaemia among primary prevention patients in Europe. In total, data from 7,641 patients (52% female, almost all Caucasian) were evaluated. Atherogenic dyslipidaemia was defined according to guideline recommendations for desirable levels of triglycerides and HDL-C.
Over 20% of these patients had either elevated triglycerides or low HDL-C levels consistent with atherogenic dyslipidaemia. Despite this, more than half of these patients (55%) were not receiving lipid lowering therapy.
These data clearly show the unmet clinical need for management of atherogenic dyslipidaemia across Europe, which warrants urgent attention.